A defect in neurotransmission involving γ-amino butyric acid (GABA) in schizophrenia was first proposed in the early 1970s. Since that time, a considerable effort has been made to find such a defect in components of the GABAergic system. After a brief introduction focusing on historical perspectives, this paper reviews postmortem and other biological studies examining the following components of the GABAergic system in schizophrenic subjects : the GABA biosynthetic enzyme, glutamate decarboxylase ; free GABA ; the GABA transporter ; the GABA A , GABA B and benzodiazepine receptors ; and the catabolic enzyme GABA transaminase. Additionally, post-mortem studies using morphology or calcium-binding protein to identify GABAergic neurons are also reviewed. Substantial evidence argues for a defect in the GABAergic system of the frontal cortex in schizophrenia which is limited to the parvalbumin-class of GABAergic interneurons.
Historical perspectives
The physiologists Ernst and Friedrich Weber (1845), Ivan Pavlov (1885) and Wilhelm Biedermann (1887) established the concept of inhibition in the nervous system and lead to the identification of inhibitory neurons by Cornelis Wiersma (1933) (Florey, 1991) . Roberts and Frankel (1950) , Awapara et al. (1950) , and Udenfriend (1950) reported the isolation of γ-aminobutyric acid (GABA) from animal brain material. Working on crayfish stretch receptors initially and later with the monosynaptic kneejerk reflex in cats, Ernst Florey reported that a Factor I had inhibitory effects in these systems (Florey and McLennan, 1955) . Factor I was later purified from beef brain and shown to be identical to GABA (Bazemore et al., 1957) . The status of GABA as neurotransmitter was not widely accepted until further studies in crustaceans established that GABA was the most common inhibitory substance in the CNS (Dudel, 1963) , that peripheral inhibitory but not excitatory neurons contained high GABA concentrations (Kravitz et al., 1963) , that inhibitory motor neurons released GABA (Otsuka et al., 1966) , and that GABA is removed from the postsynaptic cleft by an uptake process (Orkand and Kravitz, 1971) .
GABA is the major inhibitory neurotransmitter in the mammalian brain ; up to 30 % of cortical neurons in rats use GABA in neurotransmission (Bloom and Iversen, 1971) . In the monkey cortex approx. 25 % of the neurons in most regions are GABAergic ( Jones, 1990) . In addition to the neocortex, significant populations of glutamate decarboxylase (GAD)-or GABA-immunoreactive (IR) cell bodies or axon terminals have also been identified in primate brain regions including the midbrain (Holstein et al., 1986 ; Okada et al., 1971) , hippocampal formation (Schlander et al., 1987) , the thalamus (Smith et al., 1987b) , the basal ganglia (Smith et al., 1987a) , and the amygdala (Sorvari et al., 1995) .
GABA was first implicated in the pathophysiology of schizophrenia by Eugene Roberts in 1972 . He proposed that a susceptibility to schizophrenia might be due to a defect in the inhibitory GABAergic neurons control of neural circuits governing behavioral responses. This defect would be exacerbated under stressful conditions in which increased monoaminergic drive would increase disinhibitory input onto those GABA neurons, producing abnormalities of perceptual and cognitive integration (Roberts, 1972) . Since this initial proposal, a role for GABA in the pathophysiology of schizophrenia continues to be formulated in the context of complex interactions between GABA and other neurotransmitter systems. Carlsson (1988) proposed a model of psychosis that involves multiple neurotransmitters including a defective GABA-mediated inhibition of glutamatergic feedback inhibition of mesolimbic dopamine function and describes a defect in thalamic filtering of sensory and arousal input to the cortex (see also Carlsson et al., 2001 ). An abnormality in GABAergic regulation of dopamine cell burst firing has been postulated to underlie the symptoms of schizophrenia (Grace, 1991 ; Moore et al., 1999) . Others have noted, in the direct modulation of the dopaminergic system by GABAergic neurons, a potential mechanism whereby an abnormality in the GABAergic system could be involved in the dopaminergic dysfunction of schizophrenia (Carlsson, 1988 ; Fuxe et al., 1977 ; Garbutt and van Kammen, 1983 ; Stevens et al., 1974 ; van Kammen, 1979) . Squires and Saederup (1991) postulated that schizophrenia involved a GABAergic predominance caused by either hyperactive GABA A receptors or hypoactive glutamate receptors and\or destruction of counterbalancing glutamatergic neurons by neurotropic pathogens. This last model has received little ongoing support. Olney and Farber (1995) developed a model of schizophrenia in which a state of ' NMDA receptor hypofunction ' is caused by either intrinsically hypofunctioning NMDA receptors or through excitotoxic loss of NMDA receptor-bearing GABAergic neurons. This state results in excessive dopaminergic input into corticolimbic regions (also see Carlsson et al., 2001 ) with resultant further hypofunctioning of the glutamatergic system through feedback mechanisms. Several classes of compounds, including benzodiazepines (BZD), muscurinic receptor antagonist and haloperidol, blocked NMDAinduced neurotoxicity in the posterior cingulate and retrospenial regions of experimental animals. Loss of GABAergic interneurons in the hippocampal formation, possible secondary to excitotoxic injury (Benes, 1999) or to loss of glutamatergic neurons has also been hypothesized (Deakin and Simpson, 1997) . Similarly, Deutsch et al. (2001) postulates a failure of GABAergic inhibition of the AMPA\kainite class of glutamatergic receptor with a resultant cascade of excitotoxic events.
A dysfunction of α7-nicotinic acetylcholine receptor on GABA interneurons in the hippocampus (Adler et al., 1998) or disruption of interactions between the cholinergic system and 5-HT #A receptor on GABAergic interneurons in the frontal cortex (Dean, 2001 ) has been proposed as sites of pathophysiology in schizophrenia. Relationships between epilepsy, schizophrenia and the GABAergic system have been proposed (Keverne, 1999 ; Stevens, 1999) . Effects of the GABAergic system in neuro-and in particular cortico-developmental processes have been integrated into developmental hypotheses of psychosis and schizophrenia. GABAergic interneurons form the substrate for the gamma frequency oscillations postulated to synchronize brain activity in disparate regions of the brain and an abnormality in such may cause psychosis (for a review see Keverne, 1999) .
Although there is some evidence for a role for BZD and valproate in the treatment of schizophrenia, GABAergic agents have generally not been demonstrated to produce antipsychotic effects in of themselves (Wassef et al., 1999) . In-vivo pharmacological manipulation of the GABAergic system indicates that GABAergic function is potentially relevant to the pathophysiology of schizophrenia. For example, blockade of GABA receptors with picrotoxin in the prefrontal cortex of rats impairs sensorimotor gating, an effect that is reversed by haloperidol (Japha and Koch, 1999) . Conversely, enhancement of GABAergic activity by either γ-vinyl-GABA (GVG) or lorazepam in baboons inhibits dopamine transmission in the striatum as indicated by increased [""C]raclopride binding (Dewey et al., 1992) . Furthermore, GVG treatment has been shown to increases phencyclidine-induced release of dopamine in a dose-dependent manner in the rat prefrontal cortex but not in the striatum (Schiffer et al., 2001) . Hypofunctioning of the GABAergic system may be responsible for the striatal dopamine overactivity and behavioural changes noted in schizophrenic subjects (Breier et al., 1997) .
The purpose of this paper is to review the data from post-mortem and other biological studies of the GABAergic system in schizophrenia in order to provide a synthesis of what is known.
GAD
GAD, the rate-limiting biosynthetic enzyme of GABA, catalyses the decarboxylation of glutamic acid to yield GABA. Two major isoenzymes of GAD, named GAD '& and GAD '( , based on their approximate molecular weight of 65n4 and 66n6 kDa respectively, have been identified in human brain (Bu et al., 1992) . GAD '& is preferentially localized in axon terminals (Esclapez et al., 1994) , more tightly membrane associated and more often exists in an inactive apoGAD form (lacking the cofactor pyridoxal phosphate) compared with the GAD '( isoenzyme (Kaufman et al., 1991) . In rat hippocampus, most cells express transcripts of both GAD isoenzymes (Stone et al., 1999) . It has been suggested that GAD '& might preferentially synthesize GABA for vesicular release and that GAD '( may be preferentially involved in synthesis of cytoplasmic GABA (Erlander and Tobin 1991 ; Esclapez et al., 1994 ; Feldblum et al., 1993) .
Early efforts to detect an abnormality in the GABAergic system focused on determining activity levels of GAD. Seven such studies were performed on cortical tissue homogenates from parts of the temporal and frontal lobes : all but two of which reported no significant difference between controls and patients with schizophrenia in these regions (see Table 1a ) (Bennett et al., 1979 ; Bird et al., 1977 ; McGeer and McGeer, 1977 ; Perry et al., 1978 ; Spokes, 1980) . One of the divergent studies found significantly lower GAD activity in the sensory association, calcarine fissure and insular cortex in the schizophrenic group compared with controls but not in many other cortical and subcortical regions (McGeer and McGeer, 1977) . The second divergent study found significantly lower GAD activity in patients with schizophrenia in all areas examined : amygdala, hippocampus, nucleus accumbens, and putamen (Bird et al., 1977) . Whereas post-mortem interval (PMI) and age were controlled for in this study, other possible confounds such as comorbidity, medication and smoking history, diagnostic heterogeneity and cause-of-death effects were not clearly addressed. Although some studies have indicated that GAD is stable in human brain during routine post-mortem handling (Spokes, 1979 ; Spokes et al., 1979) , Crow et al. (1978) found a significant negative correlation between GAD activity levels and PMI. Although GAD activity levels is significantly decreased in brain material obtained from patients dying of protracted illness (McGeer et al., 1971 ; McGeer and McGeer 1976 ; Spokes 1979 ; Spokes et al., 1979) , most of the studies mentioned above did not control for this potential effect.
A later study of GAD activity in frontal cortex [Brodmann area (BA) 9] and caudate from chronic schizophrenics also revealed no abnormality (Hanada et al., 1987) . This study also reported lower GAD activity in the subgroup of controls that had died after a prolonged terminal illness (PTI). The control and chronic schizophrenic group were fairly well matched for age, length of PMI and sex ratios.
Before interpreting studies examining GAD gene expression by in-situ hybridization, it is important to note that GAD protein levels may not match GAD mRNA levels because of a variety of transcriptional, translational and post-translational modifications. For example, increases in GABA levels decreases GAD '( activity but does not alter GAD '( mRNA levels nor GAD '& activity in rats (Rimvall et al., 1993 ; Rimvall and Martin, 1994) . Also, elevation of GABA by vigabatrin treatment affects GAD '( protein levels differently in various brain regions of the rat (Sheikh and Martin, 1998) .
A study measured GAD '( mRNA in human prefrontal cortex by in-situ hybridization in order to determine if a postulated decrease in GABA in this region was due either to decreased gene expression or to a decrease in the number of GABAergic cells (Akbarian et al., 1995b) . Ten schizophrenic subjects were compared to ten age, gender and autolysis-time matched controls. Subjects with incomplete medical records, substance abuse histories or prolonged agonal states were excluded. Fewer GAD '( mRNA-expressing neurons with no significant overall loss of neurons were found in cortical layers I-V of the schizophrenic subjects compared with controls. The GAD '( mRNA levels, as measured by optical densities of film autoradiographs, were significantly lower in cortical layers II, III, IV and V of the schizophrenic subjects compared with controls. The authors expressed doubt that the lower mRNA levels of the schizophrenic subjects were secondary to neuroleptic treatment by noting that the single neuroleptic-naive schizophrenic subject had the lowest mRNA values.
A second study examined GAD '( mRNA expression in the prefrontal cortex of 10 schizophrenic subjects and 10 sex-matched controls (Volk et al., 2000) . The schizophrenic group did not significantly differ from the control group with respect to age, PMI, brain pH or storage time. One control and four schizophrenic subjects had lifetime diagnoses of alcohol or other substance abuse and one control subject had a lifetime diagnosis of depressive disorder not otherwise specified. Seven schizophrenic and nine control subjects had sudden deaths occurring outside of a hospital ; one schizophrenic subject was a suicide victim. This study used in-situ hybridization followed by counts of silver grains within neuronal soma from randomly selected cortical sites within specific laminar levels. Significantly (25-35 %) lower density of GAD '( mRNA-labelled neurons in cortical layers III-V was found in the schizophrenic group compared with the controls. However, mean grain density per neuron did not significantly differ across the two groups. Additionally comparison of chronic haloperidol-and benztropine mesylate-treated Cynomolgus monkeys with untreated controls indicated that this medication treatment does not affect GAD '( mRNA expression. Reelin is a protein which regulates cortical cell positioning and\or movement during development and which appears to be expressed preferentially in GABAergic interneurons in the adult human neocortex (Curran and D 'Arcangelo, 1998 ; Impagnatiello et al., 1998) . Reelin protein and mRNA levels were found to be 40-50 % lower in schizophrenic subjects compared with controls in the prefrontal cortex (BA 10 and BA 46), temporal cortex (BA 22), hippocampus, caudate and cerebellum (Impagnatiello et al., 1998) . This study also reported significantly ($ 70 %) lower GAD '( \β-actin but not GAD '& \β-actin IR optical densities in the schizophrenic subjects compared with controls.
A recent study measured GAD '& , GAD '( , and reelin mRNA levels by quantitative reverse transcriptasepolymerase chain reaction and GAD '& and GAD '( protein levels in brains from schizophrenic, bipolar and depressed subjects. Reelin mRNA, GAD '( protein and mRNA were significantly lower in the prefrontal cortex and cerebellum in schizophrenic and psychotic bipolar but not in unipolar depressed subjects without psychosis compared to normal controls (Guidotti et al., 2000) . GAD
'& mRNA levels did not differ across the diagnostic groups. Reelin and GAD '( levels were found to be unrelated to PMI or neuroleptic treatment history.
The distribution of GAD '& -immunoreactive (GAD '& -IR) puncta in the hippocampus was examined in a group of 13 schizophrenic subjects and 13 age-, gender-and PMI-matched controls . No significant difference was found in the density of GAD '& -IR puncta in contact with pyramidal or non-pyramidal cells or dispersed within the neuropil of the layers CA1-4. However, a significant positive correlation was found between the density of GAD '& -IR puncta in contact with pyramidal and non-pyramidal cells and neuroleptic exposure in the schizophrenic subjects. This finding and the fact that the two neuroleptic-naive schizophrenic subjects had the lowest density of GAD '& -IR puncta led the authors to speculate that schizophrenics might inherently have lowered density of GABAergic terminals in certain regions of the hippocampus.
The density of GAD '& -IR terminals in layers II-VI of the cingulate and prefrontal cortices did not differ between the groups ; however, the density of GAD '& -IR terminals was significantly lower in The GABAergic system in schizophrenia layers II-IV of five bipolar subjects (added in this study) compared with the normal controls (Benes et al., 2000) . Overall, neuroleptic treatment history did not appear to correlate with terminal densities in the schizophrenic group. A two-dimensional counting method was used. Three studies report lower GAD '( mRNA expression and two studies report lower GAD '( protein levels indicating that schizophrenia may be associated with less GAD '( gene expression in the prefrontal cortex. Total GAD activity and GAD '& -immunoreactivity do not appear to be altered in schizophrenia. However, it should be noted that the amount of GAD '& protein is 3-to 8-fold greater than the amount of GAD '( protein in most rat brain regions (Sheikh et al., 1999) . One possibility is that the abnormality in schizophrenia is restricted to GAD '( and is not detectable by measurement of total GAD enzyme activity. Moreover, there is evidence that the GAD '( deficit is limited to subset of neurons in the prefrontal cortex (Volk et al., 2000) .
GABA concentrations
The search for a GABAergic defect in schizophrenia also stimulated examination of GABA concentrations, both in brain tissue (see Table 1b ) and in cerebrospinal fluid (CSF). GABA concentrations in brain tissue are unaffected by agonal status but rise rapidly 1-2 h after death. The rise in GABA levels may continue even 24 h post-mortem (Perry et al., 1981) . Free CSF GABA levels are unaffected by agonal status but decline significantly with age (Perry et al., 1979 ; Spokes et al., 1979) . Most studies controlled for age and post-mortem processing, however drug history was not consistently controlled for and the study of Perry et al. (1979) included a number of controls with various neurological illnesses.
Using a single-cation exchange column method lower GABA concentrations was found in the nucleus accumbens and thalamus from schizophrenics compared with control (Perry et al., 1979) . Another study used the same method and did not find lower GABA concentrations in the nucleus accumbens, medial dorsal thalamus, frontal cortex or caudate of the schizophrenic subjects compared with controls (Perry et al., 1989) . The authors suggested that the first study was flawed by lack of anatomical accuracy with respect to dissection of the nucleus accumbens and the thalamus. Korpi et al. (1987) found no effect of diagnosis on GABA levels in the nucleus accumbens, frontal cortex, and caudate, but GABA was 37n5 % lower in the amygdala in the schizophrenic group compared with controls. Kutay et al. (1989) found lower GABA levels in multiple brain regions including the amygdala, the hippocampus, frontal pole, superior temporal cortex and thalamus. Toru et al. (1988) (see GAD section above) examined multiple cortical and subcortical regions and noted lower levels only in the posterior portion of the hippocampus of the schizophrenic group. Spokes et al. (1980) found lower GABA concentrations in the nucleus accumbens and the amygdala of the schizophrenic group compared with the controls. Absolute GABA levels in this study were in agreement with a study by but tended to be an order of magnitude higher than the other studies. In contrast to the study of Perry et al. (1979) , Cross and colleagues found no difference in GABA levels in the nucleus accumbens and thalamus between the study groups. Ohnuma et al. (1999) , using a more specific brain region definition than the studies of Korpi et al. (1987) , Perry et al. (1989) , or Kutay et al. (1989) , reported lower GABA levels in BA 9 and 10, but not 11. The PMI was longer in the control group than in the six schizophrenic subjects and possible group sex and medication effects were not ruled out. Nevertheless, this remains an interesting study as it reported a specific regional GABA level abnormality that was paralleled by increase in GABA A receptor α " subunit mRNA and decrease in GAT-1 mRNA (see below).
While most studies report low GABA levels in at least some brain regions in schizophrenia, there is no clear consensus on the affected brain regions except for a consistent finding of lower GABA in the amygdala (3 out of 3 studies). Measurement of total GABA levels may be insufficiently sensitive to consistently detect a GABAergic defect affecting only a subpopulation of GABAergic cells. The findings of lower GABA in the amygdala in schizophrenia is interesting in light of recently reported rat model in which a experimentally induced GABAergic dysfunction in the amygdala induces changes in the GABAergic system of the hippocampus. The subregional distribution of these changes is similar to findings in previous post-mortem studies of schizophrenia (Benes, 1999 ; Berretta et al., 2001 ).
CSF studies
Nine published studies examined GABA concentrations in CSF. The majority reported no difference between controls and schizophrenic patients (see Table 2 ). One study found lower baseline CSF levels in a group of schizophrenics compared with controls ; however it is not clear if a number of schizoaffective patients (previously mentioned in the report) were included in this group (Sternberg, 1980) . If so, perhaps depression explained the lower CSF GABA levels. All patients were drug free for 2 wk prior to the baseline lumbar puncture and GABA levels showed no relationship with age, sex, or degree of psychosis. This study also reported that a trial of pimozide increased GABA levels in the patients. Van Kammen et al. GABA, CSF concentration n l 7 schizophrenic, 5 schizoaffective, 2 other psychosis, compared with neurological control group Gold et al. (1980) GABA, CSF concentration H* n l 17 schizoaffective and schizophrenic Sternberg (1980) GABA, CSF concentration n l 11 schizophrenic, 29 controls Gerner and Hare (1981) GABA, CSF concentration between untreated and controls I GABA in CSF with long-term neuroleptic tx.
n l 17 controls, 9 untreated\7 treated schizophrenics Zimmer et al. (1981) GABA, CSF concentration I 45n7 %* In chronic schizophrenic subset only McCarthy et al. (1981) GABA, CSF concentration all schizophrenic H 26 %* female pts only n l 25 drug-free schizophrenic and 5 schizoaffective van Kammen et al. (1982) GABA, CSF concentration n l 20 chronic schizophenics Gerner et al. (1984) GABA, CSF concentration n l 19 schizophrenic Perry et al. (1989) GABA, CSF and plasma levels H plasma but not CSF GABA associated with prefrontal but not global sulcal widening n l 62 chronic schizophenics van Kammen et al. (1998) Plasma GABA n l 15 schizophrenics Petty and Sherman (1984) Platelet GABAtransaminase level n l 22 schizophrenics Reveley et al. (1980) Platelet GABA transaminase level n l 14 schizophrenics White et al. (1980) (1982) noted a significant decrease in the female schizophrenic sub-population compared to female controls while also reporting a tendency towards increased GABA levels with increased length of illness. That elevation of CSF GABA levels may be correlated with length of schizophrenic illness finds support in a study by McCarthy et al. (1981) in which a sub-population of chronic schizophrenics had higher GABA levels compared to controls. However, Gerner et al. (1984) did not corroborate this suggestion. An increase in CSF GABA levels has been found after 30 d treatment with sulpride and to be correlated with long-term neuroleptic treatment . However, Lichtshtein et al. (1978) noted a small but significant decrease in CSF GABA levels after 2 months of neuroleptic treatment while Gattaz et al. (1986) observed no change in free CSF GABA levels in schizophrenic patients after 3 months of haloperidol treatment. Lastly, Zander et al. (1981) reported that stopping chronic anti-psychotic medication treatment produced no change in CSF GABA levels. CSF GABA is lowered in depressed patients and therefore comorbidity must be considered in interpretation of these studies (Gerner and Hare, 1981 ; Gold et al., 1980) . A later study by Van Kammen et al. (1998) found that plasma GABA levels showed a significant negative correlation with both prefrontal sulcal widening and ventricle\brain ratio on CT scans but not to global sulcal widening in patients with schizophrenia. CSF GABA levels did not correlate with these CT measures but did show a negative correlation with age and age of onset. The disassociation between CSF and serum GABA level is puzzling. One would expect CSF GABA to reflect brain pathology better than plasma. Moreover, the plasma GABA finding may not be correct since plasma GABA levels were not found to be lower in patients with schizophrenia (Petty and Sherman, 1984) . CSF GABA is not clearly lower in schizophrenia. There are insufficient studies in which the possible confounds of anti-psychotic medication treatment, comorbidity (in particular affective disorders), length of illness and sex are all controlled. Additionally, while pharmacological studies in animals suggest that total CSF GABA concentrations are mostly related to brain GABA (Bo$ hlen et al., 1979 ; Ferkany et al., 1979) , it remains unknown to what degree this is true in humans. A defect limited to a specific subtype of GABAergic neurons, such as the chandelier subtype (see below), may not be reflected in CSF GABA levels.
GABA-transaminase
Two studies measuring GABA-transaminase, the principal catabolic enzyme for GABA in the mammalian brain, failed to find any significant difference in platelet GABAtransaminase levels between schizophrenics and controls (Reveley et al., 1980 ; White et al., 1980) . No significant effect of sex, psychotic state, length of illness or medication treatment was noted in the study by White et al. (1980) ; Reveley et al. (1980) reported no correlation between age or sex and GABA-transaminase levels. Sherif et al. (1992) measured GABA-transaminase in brain homogenates from various regions including hippocampus, amygdala, cingulate and frontal gyrus and found no significant difference between controls and undifferentiated schizophrenics. Thus, there is no evidence of altered catabolism of GABA in schizophrenia.
GABA release and uptake
Synaptosomal preparations are used in the study of synaptic function and neurotransmission in animal models. Synaptosomal preparations obtained up to 24 h postmortem from human brains are metabolically active and can release various neurotransmitters after veratrine stimulation (Hardy et al., 1982) . Using this model, Sherman et al. (1991) compared schizophrenics and controls, with PMI of 20p7 h (meanp..) and 23p7 h, respectively, and reported a significantly lower veratridine-induced release of glutamate and GABA but not aspartate in synaptosomes from temporal and frontal cortex of the schizophrenic group.
The concentration and duration of a neurotransmitter in the synaptic cleft is mostly regulated by rate of uptake by transporter proteins. Four GABA transporters have so far been described (GAT-1, GAT-2, GAT-3 and BGT-1), each varying in its localization pattern and pharmacological profile (Borden, 1996) . Simpson et al. (1989) reported significantly lower binding of [$H]nipecotic acid to GABA-uptake sites in the left BA 38 (polar temporal), bilaterally in the amygdala and hippocampus in schizophrenic subjects compared to controls (see Table 1 ). This study did have sufficient numbers of age-matched subjects and controls with similar PMI ; agonal state effects were said to have been minimized by selection of subjects who had died acutely and were matched for cause of death. Possible medication influence could not be entirely ruled out, although the authors reported that binding data from subjects that were drug-free were indistinguishable from those treated with neuroleptics.
Comparing schizophrenic subjects to age-and PMImatched controls, Reynolds et al. (1990) found lower [$H]nipecotic acid binding in both groups in the left hippocampus compared to the right side but not so in the amygdala. The schizophrenic group tended towards lower binding values in the left hippocampus compared with controls (p l 0n08) ; this tendency became statistically significant when subgroups of sudden-death cases were compared. The rationale for this distinction was that nipecotic acid binding may be reduced in patients with chronic respiratory illnesses . Simpson et al. (1992a) used [$H]nipecotic acid to measure GABA-uptake sites in a series of schizophrenic and control brains in which cerebral atrophy had been previously established and reported higher [$H]nipecotic acid binding in both groups in the right compared with left BA 38, lower left BA 38 binding and increased putaminal binding in the schizophrenic brains compared with controls. Subcortical GABA-uptake sites were further studied by Simpson et al. (1992b) in brains of 19 schizophrenic subjects who had died with the diagnosis of schizophrenia along with 22 neuropsychiatrically normal controls, matched for age, gender ratio and PMI. In contradiction to the above study, an approx. 50 % lower [$H]nipecotic acid binding was seen in the putamen bilaterally in the schizophrenic group. The binding of this ligand did not differ between the two groups in the caudate, globus pallidum or nucleus accumbens. This study also reported no correlation between binding to GABA-uptake sites and length of the neuroleptic-free period in a subgroup of medication-free schizophrenics. Simpson et al. (1998a) measured [$H]nipecotic acid binding to GABA-uptake sites in 11 brain regions from a group of 12 neuroleptic-treated chronic schizophrenia (9 males, 3 females) and a group of normal controls (14 males, 5 females). No significant overall difference was noted between the two groups in any of the 11 temporal and frontal lobe areas. The authors suggested these findings might be influenced by low uptake measurements in three of the female controls and large variance in the hippocampal data.
A recent study examined [$H]nipecotic acid binding in the basal ganglia from three brain collections (Manchester, Gothenburg and Runwell) (Simpson et al., 1998b) . The schizophrenic (n l 12-18) and the control subjects (n l 19-22) did not differ with respect to age, PMI or storage time. [$H]Nipecotic acid binding was higher in the schizophrenic groups compared to controls in the heads of the caudate and putamen of the Manchester collection. Higher binding was also noted in the caudate of the female schizophrenic subjects of the Gothenburg collection ; the caudate-binding values obtained from this collection were 2-to 3-fold greater than those seen in the Manchester collection. Caudate-binding values were not reported for the Runwell collection.
Several studies indicate that GABA uptake may be moderately lower in both the hippocampus ([$H]nipecotic acid binding studies) and in BA 9 (GAT-1 mRNA studies, see below) of schizophrenic subjects compared with controls. GABA-uptake sites may reflect GABA terminal distribution and appear to be sufficiently sensitive to detect impaired input. There are approx. 100 times more GABA terminals on the apical dendrites than on the proximal axon segment. Lewis et al. (2000) reported a deficit of the chandelier GABAergic neurons, which specifically target the proximal axon segment. Such a localized GABAergic input defect may not be equally detectable by assays of GAT, GAD, brain GABA or CSF GABA.
GABA receptors
Two types of GABA receptors have been identified in the human brain : the GABA A receptor, which is associated with a chloride channel and mediates fast inhibitory synaptic transmission and the GABA B receptor which is associated with potassium and calcium channels and is a G protein-linked metabotrobic receptor (Bowery, 2000 ; Olsen and Homanics, 2000) . The GABA A receptor is thought to be a heteropentameric glycoprotein composed of subunits of six distinct subclasses : α, β, γ, δ, ε and ρ, the largest being the α subclass which includes six known members (α " -' ). In the adult mammalian brain, the subunit combination of α " β # γ # is thought to be the most common (Olsen and Homanics, 2000) . Bennett et al. (1979) used tritiated GABA as a ligand (see Table 3 ) and reported that post-mortem binding in frontal cortex homogenates of schizophrenics was not significantly different from controls. The study did report alterations in serotonergic receptor binding. Control and schizophrenia groups were not well matched for age or sex ratio. The authors reported no correlation between PMI or time frozen and receptor-binding results ; however agonal and possible drug effects could not be excluded. Hanada et al. (1987) measured GABA receptor binding using the GABA agonist [$H]muscimol and observed significantly higher binding (B max ) in both caudate and BA 9 in the chronic schizophrenic group as a whole compared with controls. This finding survived subdivision into sudden death and PTI subgroups in both regions of the sudden-death subgroup but not in the caudate of the PTI subgroup. Benes et al. (1992) examined GABA A receptor binding in the anterior cingulate gyrus in order to test a hypothesis that upregulation of these receptors would follow the loss of cortical interneurons reported to occur in this region and the prefrontal cortex of chronically psychotic patients (Benes et al., 1991) . By using a bicuculline-sensitive [$H]muscimol binding assay and a nuclear-track, coverslipemulsion technique, they counted autoradiographic grains per neuron and per 200 µm# of neuropil. [$H]Muscimol binding on neuronal cell bodies is 84 % higher in layer II and 74 % higher in layer III in the schizophrenic group compared to normal controls. In layer I neuropil [$H] muscimol was increased in the schizophrenic group. PMIs were similar in the two groups ; however, group sex ratios and cause of death were not mentioned. The schizophrenic group was significantly younger than the control group but the authors discounted the possibility of a confounding effect as both younger and older schizophrenics had elevated numbers of receptor sites compared to controls. The authors believed that elevation of [$H]muscimol binding was not secondary to neuroleptic treatment, as a neuroleptic-naive and a minimally exposed patient both had elevated binding. Benes et al. (1996b) also used a bicuculline-sensitive [$H]muscimol-binding assay to examine GABA A receptor levels in the prefrontal cortex (BA 10) of 7 schizophrenic subjects and 16 normal controls. No difference in average size of neuronal cell bodies was observed between the two groups ; however, more grains per cell were found on the large (pyramidal) neurons of layers II-VI (greatest in layer II) and on the small (non-pyramidal) neurons of layer VI in the schizophrenic subjects compared with controls. Although the control group was significantly older and had a significantly shorter mean PMI compared to the schizophrenic group, no correlation was found between these potential confounds and GABA A binding. Two schizophrenic subjects without history of neuroleptic exposure had binding values that were lower than the neuroleptic-treated schizophrenics and similar to the average of the control group. These same two neurolepticfree schizophrenic subjects had exhibited a higher layer II GABA A receptor-binding value in a previous study of the anterior cingulate gyrus (Benes, 1992) compared with the schizophrenic group as a whole indicating that the higher GABA A receptor binding in the prefrontal cortex of the schizophrenic group may not be simply a medication effect. Benes et al. (1996a) , using brain tissue from the same subjects in the above study (with the addition of one subject to the schizophrenia group), reported higher [$H]muscimol in subregions of the hippocampus of the schizophrenic group compared with controls. Increases of 90 % (stratum oriens of CA3), of 74 % (stratum pyramidales of CA3), of 60-73 % (subiculum and presubiculum) and of 22-36 % were seen in the CA1 subregion (ranges indicating layer differences within a subregion). Increased GABA A binding in the subregion CA3 was limited to non-pyramidal cells while binding increases in the CA1 subregion were noted only on pyramidal cells. The author postulated that these subregional increases in GABA A receptor binding might reflect increased vulnerability of certain subpopulation of GABAergic neurons to injury during development. Dean et al. (1999) In animal experiments, reduced neuronal activity can lead to decreased gene expression for a number of GABA A receptor subunits (Hendry et al., 1990 (Hendry et al., , 1994 Huntsman et al., 1994) . Akbarian et al. (1995a) used in-situ hybridization histochemisty to quantitate mRNA of the
, β # and γ # in the prefrontal cortex. The schizophrenic and control groups showed similar laminar gene expression patterns with highest α " , β # , and γ # expression in layers III and IV, highest α # and β " expression in layer II, and higher α & expression in layers IV-VI with peak expression in layer IV. No significant difference in expression of any of the subunit genes was noted between the two groups. The 12 schizophrenic and 12 control subjects were matched for age, sex and PMI. Huntsman et al. (1998) used in-situ hybridization histochemisty and semi-quantitative reverse transcription-PCR to measure the relative abundance of two species of mRNA of the γ # subunit of the GABA A receptor in the prefrontal cortex of five matched pairs of schizophrenics and controls. The γ # subunit, which is necessary for high-affinity BZD binding, exists in two forms : short (γ # S) and long (γ # L), which differ by a functionally significant 8-amino-acid insert. The laminar pattern of γ # subunit mRNA labelling was consistent with past reports for both schizophrenics and controls. Although the schizophrenic group was found to have lower γ # message labelling in each of the six cortical levels, this difference reached statistical significance in only layers II and III. The authors reported a lower level (average 51n7%, p 0n001) of short (γ # S) mRNA (but only 16n9% lower long (γ # L) mRNA) in the prefrontal cortex of the schizophrenic group compared with their matched controls. The authors speculated that this relative overabundance of the long (γ # L) mRNA in the prefrontal cortex of schizophrenics would result in GABA A receptors of decreased functionality. Agonal effects were not discussed but the authors expressed concern about possible medication effects. Ohnuma et al. (1999) measured α " subunit mRNA expression in BA 9, 10, and 11 of 6 schizophrenics and 12 controls and found a general increase in the schizophrenic group which attained statistical significance in the large cells of layer V of BA 9 and in layer III of BA 10. The patient group was comprised of neuroleptic-treated chronic schizophrenics who had a shorter averaged PMI than controls.
One study examined the anatomical distribution of immunolabelled GABA B receptors in the hippocampus of 5 chronic schizophrenics and 3 controls matched for age and PMI (Mizukami et al., 2000) . Schizophrenic subjects were reported to be resistant to neuroleptic treatment ; however cause of death and treatment status at time of death were not reported. The authors found less immunolabelling of the mossy cells in CA4 and the pyramidal cells in CA1-3 in the schizophrenic subjects compared to the controls. The granule cells of the dentate gyrus appeared unstained in the schizophrenic subjects whereas staining in controls was reported as moderate. In all regions the degree of staining of interneurons was similar in both subject types.
In summary, GABA A receptor binding is higher in schizophrenia in cortical regions generally regarded as important in the pathophysiology of schizophrenia. Somewhat at odds with this observation is the tendency towards less subunit mRNA in the prefrontal cortex of schizophrenic subjects in two studies. These receptor changes may represent upregulation in response to reduced GABAergic input. What remains unclear is the functional significance of alterations in binding or gene expression. The functional response mediated by these receptors may be impaired and counteract the benefits of up-regulation. Studies of receptor coupling and signal transduction are needed.
BZD binding studies
The therapeutic efficacy of BZDs as anxiolytic agents is attributed to their ability to potentiate GABA A receptormediated inhibition by increasing the receptors affinity for GABA. Selectivity of BZD binding to the GABA A receptor is determined by specific amino-acid residues in the γ and the α subunits (Mo$ hler et al., 2000) . Kiuchi et al. (1989) assayed [$H]flunitrazepam binding in homogenates from multiple cortical regions of brains from schizophrenic and control subjects and reported significantly higher binding in the medial frontal cortex orbitofrontal cortex, orbital cortex, medial and inferior temporal gyri, cornu Ammonis 1-3 of the hippocampus and putamen of the schizophrenic subjects compared with controls (see Table 3 ). No significant differences in binding were found in other areas. Medication effects might be a confound in this study and agonal state issues were unaddressed. Reynolds and Stroud (1993) found no difference in [$H]flunitrazepam binding in hippocampal homogenates between a group of 15 schizophrenic subjects and normal controls with matching sex compositions and ages. Medication history was not reported. Squires et al. (1993) found lower [$H]flunitrazepam binding in a schizophrenic group compared with controls, with differences reaching statistical significance in the somatomotor and cingulate cortex but not in other cortical regions such as the frontal cortex. Lower binding in the schizophrenic group was also noted in the globus pallidus, hippocampus and cerebellar cortex (vermis) but not in the putamen. The authors speculated that these reductions in binding might represent the loss of glutamatergic (pyramidal) cells. Four of 15 schizophrenic subjects were suicide victims whereas the nine controls were victims of traffic accidents. Past studies of BZD receptors in suicide victims found altered (Cheetham et al., 1988) and unaltered binding (Manchon et al., 1987 ; Rochet et al., 1992 ; Stocks et al., 1990) ; therefore the use of suicide victims may be a confound. The schizophrenic subjects were reported to be drug-free for months prior to death ; the average PMI appears to have been significantly longer for the schizophrenic group (Squires et al., 1993) .
To further study the relationships between suicide, schizophrenia and BZD receptor binding, Pandey et al. (1997) examined binding of the selective, high-affinity radioligand [$H]RO15-1788 in prefrontal cortex B max values (BA 10) homogenates from 13 suicide victims without schizophrenia, 8 schizophrenic suicide victims, 5 non-suicide schizophrenic subjects and 15 normal controls. The B max of BZD receptors in the prefrontal cortex was higher in suicide victims, largely due to increased B max in the suicide victims who had died by violent means. Overall, the B max of the schizophrenic subjects did not differ from controls ; however, the sample size was small. Benes et al. (1997) assayed BZD binding with [$H]flunitrazepam in hippocampal tissue sections from the same schizophrenic and control subjects used in a previous study (Benes et al., 1996a) . After normalization of the data, the ratios of BZD binding to GABA A binding in controls was similar throughout most of the hippocampal region except in the inner and outer molecular layers of the area dentata where higher BZD binding was observed.
[$H]Flunitrazepam binding was found to be only modestly higher in the stratum oriens of the CA3, the subiculum and the presubiculum of the schizophrenic subjects compared with controls. As the magnitude of these increases did not match the increases in GABA A binding in these regions, the authors speculated that the regulation of the BZD-binding elements might be uncoupled from the regulation of the GABA A receptor. The authors noted that such an uncoupling phenomena was reported in the cerebellum of the stagger mouse (Luntz-Leybman et al., 1995) . Taken as a group, these papers on BZD binding in schizo-The GABAergic system in schizophrenia phrenia do not provide a consensus about BZD binding in examined regions of the frontal or temporal lobes.
Calcium-binding proteins as markers of GABAergic neurons
In the prefrontal cortex of primates, sub-populations of GABAergic interneurons can be classified based on morphological characteristics, synaptic targets or the presence of different calcium-binding proteins (Conde! et al., 1994 ; Lund and Lewis, 1993) . The calcium-binding protein parvalbumin is found primarily in the wide-basket and chandelier subclasses of GABA neurons. The axon terminals of the chandelier neurons synapse on the initial axon segments of pyramidal cell. The axon terminals of the wide-basket neurons synapse on the cell bodies and dendrites of pyramidal cells. GABA neurons in the doublebouquet subclass contain calretinin (CR) and have terminal axons that synapse onto the dendritic shafts of both pyramidal and non-pyramidal neurons. The parvalbumincontaining GABA neurons of the chandelier subclass have attracted the most scrutiny in studies of schizophrenia because their synaptic targeting of the axon initial segment of pyramidal cells suggest a strong influence on 
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Lewis (2000) Parvalbumin-IR neurons BA 9 and BA 46 H* Reynolds and Beasley (2001) Calbindin-IR neurons H* Calretinin-IR neurons pyramidal cell output ; they also appear to receive direct synaptic input from mesocortical dopamine and thalamocortical glutamatergic projection (Muly III et al., 1998 ; Sesack et al., 1995 Sesack et al., , 1998 ).
An early study of calcium-binding proteins in schizophrenia used CR and calbindin (CB) immunohistochemical labelling of tissue from prefrontal cortical areas 9 and 46 obtained from 1 schizoaffective and 4 schizophrenic subjects and 5 controls matched for age, sex and PMI (see Table 4 ) (Daviss and Lewis, 1995) . One of the schizophrenic subjects died by suicide ; the cause of death listed for the remainder of subjects are consistent with short agonal periods. The authors found a 50-70 % greater density of the CB-immunoreactive (CB-IR) and a 10-20 % (non-significant) greater density of the CR-immunoreactive (CR-IR) non-pyramidal neurons of both cortical areas in the schizophrenic group compared with the controls. The authors noted small sample size, lack of stereological methodology and potential medication effects as caveats. Beasley and Reynolds (1997) used a monoclonal antibody against parvalbumin to quantitate parvalbumincontaining chandelier and wide-basket GABA neurons in tissue sections from BA 10 obtained from schizophrenic and control subjects. The authors reported fewer parval-bumin-positive cells in the schizophrenic subjects compared with the normal controls. Differences reached statistical significance only in layers III and IV. No group difference was found in cortical thickness. Age, sex, and duration of illness did not have an effect on cell counts. The authors did not use a stereological method. The question of an effect of neuroleptics on parvalbumin expression and cell counts was left open. Woo et al. (1997) examined parvalbumin-IR local circuit GABAergic neurons in tissue sections from BA 9, 46 (prefrontal) and 17 (visual) obtained from 15 schizophrenic subjects and sex-matched controls and detected no significant difference in their densities between the schizophrenics and controls. As the authors found no somal size differences between the two subject groups, the inability to perform absolute cell counts was not thought to be a confound. However, differences in neuropil or tissue shrinkage could be critical for density measures. Cause of death and medication histories of the subjects were not reported.
More parvalbumin-IR GABA interneurons in layers Va and Vb of the anterior cingulate cortex was found in schizophrenics compared with controls, but the density of Nissl-stained neuron profiles did not differ in any of the layers (Kalus et al., 1997) . Stereological methods were not employed. The two groups differed significantly in average PMI ; disparities in tissue shrinkage, medication histories and agonal states may have confounded the results. Woo et al. (1998) used an antibody against the GABA transporter GAT-1 to identify the distinctive vertical arrays of chandelier axons known as cartridges. This study included 15 schizophrenic subjects matched by age, sex and PMI to both a normal control and a nonschizophrenic psychiatric group. The relative density of GAT-1-IR cartridges, assessed by stereological methods, was lower in the schizophrenic subjects across layers II-VI in both BA 9 and 46 compared with both the psychiatric and normal controls. Density of CR-IR axon boutons in layers II-IIIa did not differ between the schizophrenic and normal control subjects. The schizophrenic group included two suicide victims, the psychiatric group included 12 suicide victims and normal control group had no suicide cases ; cause of death in the remaining subjects was not reported. The majority of the schizophrenic group had been treated with neuroleptic medication ; however, the authors noted that two of the schizophrenic subjects who had been off medications for a significant time before death also had GAT-1 cartridge densities that were lower than control densities. Pierri et al. (1999) also examined the laminar densities of GAT-1-IR cartridges and found that in comparison with a psychiatric and a normal control group, a group of 30 schizophrenics [15 of the comparison triads had been used in a previous study (Woo et al., 1998) ] had significantly lower GAT-1-IR cartridge density in layers II-IIIa and IIIb-IV. The schizophrenic subjects were matched to controls by sex, age and PMI. Significant numbers of subjects in both the schizophrenia group and psychiatric control group but not the normal control group had histories of substance abuse or were suicide victims. Medication effects were not apparent on GAT-1-IR cartridge density in prefrontal cortex of male Cynomolgus monkeys were treated for 9-12 months with haloperidol decanoate and benztropine mesylate.
GAT-1 mRNA levels were quantitated in 10 pairs of schizophrenic subjects and controls (see Volk et al., 2000) in a study which sought to determine if lower GAT-1 density in the prefrontal cortex was accompanied by lower GAT-1 gene expression (Volk et al., 2001) . A threshold of 2-fold background was used to exclude nonspecific labelling and a somal size criterion of greater than 50 µm# was used to exclude glial cells. GAT-1 mRNApositive neuron density was lower (21-33 %) in layer I, layer II, the superficial portion of layer III, and at the boundary of layers III-IV in the schizophrenic group compared with controls. Grain density per neuron was also significantly decreased (11 %, p l 0n009) in the schizophrenic group only at the layers III-IV border and cross-sectional size did not differ significantly between the two groups. This study also compared GAT-1 mRNA labelling between 4 haloperidol-and benztropine mesylate-treated Cynomolgus monkeys and 4 untreated controls and reported that after 9-12 months of treatment there were no significant differences. The authors concluded that GAT-1 expression in the prefrontal cortex of schizophrenics is unaltered overall, but that it may be lower in the chandelier class of GABAergic cells. The authors noted that lower density of GAT-1 mRNApositive neurons is congruent with a previous finding of laminar-specific decreases in GAD '( -positive neuronal but not synaptophysin-mRNA-positive neuronal densities (Volk et al., 2000) .
Overall, it appears that there may be fewer GAT-1-IR axon cartridges consistent with less GABAergic inhibition at the proximal axon segment of pyramidal cells by parvalbumin-positive chandelier cells. Of the calciumbinding proteins, parvalbumin alone is expressed later in foetal development in GABAergic interneurons. Late expression of parvalbumin is hypothesized to lead to a ' window of vulnerability ' in which an insult to the foetus leads to glutamate receptor stimulation and cytotoxic calcium influx (Reynolds and Beasley, 2001 ). An important question to be resolved is whether or not the abnormality in the parvalbumin-class interneurons involves a loss of such cells (Beasley and Reynolds, 1997 ; The GABAergic system in schizophrenia Beasley, 2001) or is limited to a decrease in the number of axon cartridges . Of the calcium-protein positive GABAergic interneurons in the adult mouse cortex, parvalbumin-class interneurons alone do not express reelin protein, suggesting that the abnormality in this class of interneurons is not related to the deficits in reelin reported in schizophrenia (Alca! ntara et al., 1998 ; Guidotti et al., 2000 ; Impagnatiello et al., 1998) .
Non-pyramidal cell counts
A non-stereological study of 9 chronic schizophrenic, 9 schizoaffective and 12 control subjects reported fewer small neurons in layers I and II of the prefrontal cortex (BA 10) and in layers II-VI of the anterior cingulate (BA 24) in the two patient groups compared with controls (Benes et al., 1991) These decreases tended to be greater in the schizoaffective subgroup. Glial cell numbers did not differ between the groups nor did pyramidal cell numbers except in layer V of the patient group in which had significantly higher counts were observed.
A recent stereological study of post-mortem tissue from the hippocampus obtained from 10 schizophrenic and 10 age-and PMI-matched controls found fewer numbers of non-pyramidal cells in CA2 sector of the schizophrenics compared with controls . A similar finding was reported in a group of four bipolar patient also included in this study. Numbers of pyramidal cells did not differ between the groups. Three of the schizophrenic subjects were suicide victims and both groups may have been partly composed of subjects with prolonged agonal intervals. Two schizophrenic subjects who were neuroleptic-free for at least 1 yr also had decreased non-pyramidal counts in the sector CA2. There may be fewer non-pyramidal neurons in the prefrontal cortex in schizophrenia, further evidence of a GABAergic deficit.
Conclusion
Substantial evidence argues for a defect in the GABAergic system of the frontal cortex in schizophrenia, particularly in the prefrontal region and to a lesser degree in the anterior cingulate gyrus. A coherent pattern can be described : lower GAD '( mRNA and protein (Akbarian et al., 1995b ; Guidotti et al., 2000 ; Impagnatiello et al., 1998 ; Volk et al., 2000) is possibly paralleled by lower GABA concentrations (Kutay et al., 1989) , less release of GABA (Sherman et al., 1991) , lower GAT-1 mRNA (Ohnuma et al., 1999 ; Volk et al., 2001 ) and up-regulation of GABA A sites (Benes et al., 1992 (Benes et al., , 1996b Dean et al., 1999 ; Hanada et al., 1987) .
Use of calcium-binding proteins as markers indicates that a GABAergic defect may be specific for the chandelier class interneurons (Beasley and Reynolds, 1997 ; Lewis, 2000 ; Reynolds et al., 2000) . Fewer chandelier-class GABAergic synapsing onto cortical pyramidal cells may contribute to impaired ability to perform dopaminedependent functions such as working memory (GoldmanRakic, 1996 ; Lewis et al., 1999) . Decreases in dopamine input into the prefrontal cortex may also lead to decreased cortical glutamatergic input to the ventral striatum\ ventral pallidum. This may lead to a decrease in tonic dopamine release resulting in a decreased ability to regulate phasic dopamine release in mesolimbic circuits leading to positive symptoms (Grace, 1991 ; Moore et al., 1999) . Alternatively, a decrease in cortical glutamatergic activity onto striatal GABAergic projection neurons may lead to a decrease in the inhibitory effects of the indirect striatothalmic pathway on the thalamus. Such an effect may decrease the ability of the thalamus to filter off excessive or irrelevant stimuli (Carlsson et al., 2001 ). Some evidence is also presented for the existence of GABAergic defect in regions of the temporal lobe, in particular in the hippocampus. In this region, there also appears to be deficits in GABA uptake Simpson et al., 1989) with increased (and possibly compensatory) GABA A receptor binding (Benes et al., 1996a) . Studies of BZD receptor binding have generated conflicting results in both frontal cortical regions and in the hippocampus. The only study employing the use of tissue sections reported modest regional increases in hippocampal BZD binding in the schizophrenic group that suggest an uncoupling of the BZD and GABA A receptors (Benes et al., 1997) . Whether or not this reflects a true uncoupling of the BZD and GABA A receptors and is related to an abnormality in γ-subunit processing (Huntsman et al., 1998) remains to be determined.
The full anatomical distribution of post-mortem findings in the GABAergic system in schizophrenia is not known with certainty because most studies have selectively examined certain regions. Systematic mapping studies of the human neocortex are lacking for most GABAergic markers. The authors also wish to emphasize that many of the findings reviewed in this article remain unreplicated. Interpretation of abnormal findings in the GABAergic system in schizophrenia should be tempered by lack of information on functional changes in GABAergic transmission, the awareness that schizophrenia may be a heterogeneous set of disorders and that multiple defects may cause the same basic illness. One also needs to keep in mind the likely complexity of the GABAergic system ; a system in which the major synthetic enzyme occurs in two distinct forms at the genomic level, the number of recognized receptor subtypes is approx. 20 (Olsen and Homanics, 2000) . Complexity is also added by the fact that GABAergic neurons interact with multiple neurotransmitters systems, exist in at least 14 distinct electrophysiological subtypes (Gupta et al., 2000) and are involved in virtually every brain circuit. Additionally, one needs to use caution in interpreting findings from any study that has not controlled for medication history. For example, chronic haloperidol treatment increases the size of GABA-IR axosomatic terminals in the medial prefrontal cortex of rats (Vincent et al., 1994) and increases GABA receptor binding in the substantia nigra, the latter effect being partially reversed after 8 d of treatment cessation (Huffman and Ticku, 1983) . Part of the antipsychotic effects of medications such as haloperidol may be due to such secondary changes in the GABAergic system.
